Nutex Health (NASDAQ:NUTX) Sets New 1-Year High After Insider Buying Activity
Nutex Health (NASDAQ:NUTX) reached a new 52-week high of $137.32 after insider buying by CFO Jon Christian Bates, who purchased 1,000 shares at $81.81 each. The stock last traded at $129.67. Maxim Group raised its target price from $75 to $100, maintaining a "buy" rating. Nutex reported $11.12 EPS, beating estimates, with revenue of $81.30 million. Institutional investors hold 5.32% of the company, which operates in healthcare services across three segments: Hospital, Population Health Management, and Real Estate.
Shares of Nutex Health Inc. (NASDAQ:NUTX - Get Free Report) reached a new 52-week high during trading on Tuesday after an insider bought additional shares in the company. The company traded as high as $137.32 and last traded at $129.67, with a volume of 212340 shares. The stock had previously closed at $132.03.
Specifically, CFO Jon Christian Bates acquired 1,000 shares of the stock in a transaction dated Tuesday, April 8th. The stock was purchased at an average cost of $81.81 per share, for a total transaction of $81,810.00. Following the acquisition, the chief financial officer now owns 4,888 shares in the company, valued at $399,887.28. The trade was a 25.72 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
Wall Street Analyst Weigh In
Separately, Maxim Group lifted their target price on shares of Nutex Health from $75.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th.
View Our Latest Stock Report on Nutex Health
Nutex Health Price Performance
The firm has a fifty day moving average of $64.12 and a two-hundred day moving average of $42.85. The company has a current ratio of 1.77, a quick ratio of 1.74 and a debt-to-equity ratio of 3.36. The company has a market capitalization of $716.82 million, a PE ratio of -13.81 and a beta of 0.27.
Nutex Health (NASDAQ:NUTX - Get Free Report) last announced its quarterly earnings data on Monday, March 31st. The company reported $11.12 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $11.21. Nutex Health had a negative return on equity of 51.27% and a negative net margin of 14.09%. The firm had revenue of $81.30 million during the quarter, compared to the consensus estimate of $81.13 million.
Institutional Investors Weigh In On Nutex Health
Large investors have recently added to or reduced their stakes in the company. Topline Capital Management LLC purchased a new stake in shares of Nutex Health during the fourth quarter worth about $5,690,000. American Century Companies Inc. bought a new position in Nutex Health during the 4th quarter valued at approximately $1,362,000. Ancora Advisors LLC purchased a new stake in Nutex Health in the 4th quarter worth approximately $1,334,000. Drive Wealth Management LLC purchased a new stake in Nutex Health in the 4th quarter worth approximately $1,122,000. Finally, Essex Investment Management Co. LLC grew its position in shares of Nutex Health by 45.4% in the 4th quarter. Essex Investment Management Co. LLC now owns 105,809 shares of the company's stock worth $3,353,000 after buying an additional 33,024 shares during the last quarter. Institutional investors own 5.32% of the company's stock.
About Nutex Health
(Get Free Report)Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.
See Also
- Five stocks we like better than Nutex Health
- Short Selling - The Pros and Cons
- Why NVIDIA Stock Could Soar Despite Wall Street Downgrades
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold
- Trading Halts Explained
- 3 Hot New IPOs Defying the 2025 Market Slump
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Nutex Health Right Now?
Before you consider Nutex Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutex Health wasn't on the list.
While Nutex Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
